---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-008288"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:20:35.405455+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences Q3 net loss ~$0.5M, revenue up 67% to $1.0M; cash extended by $3.9M offering

## Summary
- Net loss of approximately $0.5M for Q3 2025; revenue rose 67% YoY to $1.0M on higher Takeda royalty payments.
- R&D expenses increased 105.6% to $0.8M due to manufacturing and pre-clinical work; G&A rose 9.3% to $0.8M on legal costs.
- Cash at Sept 30, 2025 was ~$4.1M; subsequent October 2025 offering added ~$3.9M net proceeds, extending runway.
- DNase I program advancing toward IND submission and Phase 1 for pancreatic and solid tumors; preclinical studies ongoing.
- PeriNess agreement for investigator-initiated studies in Israeli centers under regulatory approval process.

## SEC filing metadata
- accession: 0001683168-25-008288
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316825008288/0001683168-25-008288-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316825008288/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-008288
- JSON: https://secwatch.observer/filing/0001683168-25-008288.json
- Plain text: https://secwatch.observer/filing/0001683168-25-008288.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.